Novo Nordisk A/S $ 66.86 -0.23 (-0.34%)
Warning! GuruFocus has detected 1 Severe warning sign with NVO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for NVO (Novo Nordisk A/S) from 1990 to Aug 13 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Novo Nordisk A/S stock (NVO) PE ratio as of Aug 13 2020 is 24.21. More Details
Novo Nordisk A/S PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Novo Nordisk A/S PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare OCSE:GMAB OCSE:ALK B OCSE:BAVA OCSE:ZEAL OCSE:ORPHA ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY HKSE:02269 HKSE:01177 SZSE:300122 NAS:BMRN XBRU:UCB NAS:ALNY
Traded in other countries NNOR.Austria NOVO B.Denmark NOVA.Germany NVON.Mexico NOVOB.Switzerland 0QIU.UK NVO.USA
Address Novo Alle 1, Bagsvaerd, DNK, DK-2880
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.